Andy C Rawstron
Overview
Explore the profile of Andy C Rawstron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Tute R, Cook G, Cairns D, Brown J, Cavenagh J, Ashcroft A, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):431-434.
PMID: 38195983
No abstract available.
2.
Robinson J, Md Yusof M, Davies V, Wild D, Morgan M, Taylor J, et al.
EBioMedicine
. 2022 Nov;
86:104343.
PMID: 36371989
Background: Rituximab is widely used to treat autoimmunity but clinical response varies. Efficacy is determined by the efficiency of B-cell depletion, which may depend on various Fc gamma receptor (FcγR)-dependent...
3.
Arnold J, Vital E, Dass S, Aslam A, Rawstron A, Savic S, et al.
Front Immunol
. 2022 Jan;
12:803175.
PMID: 35095887
Background: Time to relapse after rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is variable, and optimal retreatment strategy has remained unclear. In AAV following rituximab induction,...
4.
Kwok M, Oldreive C, Rawstron A, Goel A, Papatzikas G, Jones R, et al.
Blood
. 2019 Dec;
135(6):411-428.
PMID: 31794600
Spontaneous regression is a recognized phenomenon in chronic lymphocytic leukemia (CLL) but its biological basis remains unknown. We undertook a detailed investigation of the biological and clinical features of 20...
5.
Hillmen P, Rawstron A, Brock K, Munoz-Vicente S, Yates F, Bishop R, et al.
J Clin Oncol
. 2019 Jul;
37(30):2722-2729.
PMID: 31295041
Purpose: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and...
6.
Md Yusof M, Vital E, McElvenny D, Hensor E, Das S, Dass S, et al.
Arthritis Rheumatol
. 2019 May;
71(11):1812-1823.
PMID: 31131994
Objective: To evaluate predictors of serious infection events (SIEs) during rituximab (RTX) therapy and effects of hypogammaglobulinemia on SIE rates, and humoral response and its persistence after discontinuation of RTX...
7.
Holmes K, Sadreev I, Rawstron A, Munir T, Westhead D, Hillmen P, et al.
Oncogenesis
. 2019 May;
8(5):32.
PMID: 31076570
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries. It has recently been shown that the homogeneity of the chromatin landscape between CLL cells contrasts with the...
8.
Rawstron A, Kreuzer K, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al.
Cytometry B Clin Cytom
. 2017 Oct;
94(1):121-128.
PMID: 29024461
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of...
9.
Collett L, Howard D, Munir T, McParland L, Oughton J, Rawstron A, et al.
Trials
. 2017 Aug;
18(1):387.
PMID: 28830517
Background: Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line...
10.
Oughton J, Collett L, Howard D, Hockaday A, Munir T, McMahon K, et al.
Trials
. 2017 Jul;
18(1):353.
PMID: 28747208
Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of...